Disease Area

Opioid Use Disorder

PreclinicalPhase IPhase IIPhase IIINDAFDA ApprovalPartner
Phase I
Phase II
Phase III
FDA Approval

Our programs and progress

OPNT006, under development, is an ultra long-acting implant containing an opioid antagonist. It would be surgically implanted beneath the skin (for example, above the biceps muscle or in the abdominal area) and slowly release the drug for up to 6 months.  Naltrexone, available as both a tablet and a monthly injection, is currently approved for treating OUD. By occupying opioid receptors in the brain, naltrexone and other opioid antagonists can block the reinforcing effects of opioids (that is, to produce a “high”). If this blockade can be sustained, the patient will “learn” that administering an opioid will not produce the desired reinforcing effect.

Because addiction is a chronic, relapsing disorder, the majority of patients beginning treatment with antagonist therapy do not remain in therapy.  However, the ability to make “one good decision” to receive an implant every six months may allow sufficient time for the patient to “unlearn” some of the behaviors associated with OUD while protecting the patient from an overdose if the patient misuses opioids.

The long-acting opioid antagonist implant is in preclinical development.